Talphera

Talphera ROE

The Return on Equity (ROE) of Talphera (TLPH) as of Nov 6, 2026 is -83.89 %. In the previous year, Return on Equity (ROE) was -162.53 % — a change of -48.39% (higher).

ROE

-83.89 %

YoY

-48.39%

Last updated:

In 2025, Talphera's return on equity (ROE) was -83.89 %, a -48.39% increase from the -162.53 % ROE in the previous year.

The Talphera ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-1,108.61 USD
Jan 1, 2019
128.54 USD
Jan 1, 2020
72.43 USD
Jan 1, 2021
97.79 USD
Jan 1, 2022
194.90 USD
Jan 1, 2023
-130.43 USD
Jan 1, 2024
-162.53 USD
Jan 1, 2025
-83.89 USD
The Talphera ROE history
YEARROEYoY
-83.89 %-48.39%
-162.53 %+24.61%
-130.43 %-166.92%
194.90 %+99.31%
97.79 %+35.01%
72.43 %-43.65%
128.54 %-111.60%
-1,108.61 %-885.78%
141.08 %-82.55%
808.64 %-1,197.44%
-73.68 %+3.07%
-71.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Talphera Stock analysis

What does Talphera do? Talphera Inc develops and commercializes therapies for medically supervised settings, focusing on nafamostat-based products. The company's Niyad targets regional anticoagulants for dialysis circuits in acute kidney injury and chronic kidney disease patients. LTX-608 is an intravenous formulation for potential treatment of viral infections, ARDS, DIC, and acute pancreatitis. Pre-filled syringes Fedsyra and PFS-02 are also under development. The firm sells these products to hospitals, dialysis centers, and medical facilities requiring specialized therapies in controlled environments. Niyad is designed for use during continuous renal replacement therapy and hemodialysis procedures, primarily targeting healthcare providers in hospital settings and dialysis centers. LTX-608 aims to address viral and inflammatory conditions, with potential buyers including hospitals treating respiratory and coagulation disorders. The pre-filled syringes Fedsyra and PFS-02 serve as delivery systems for these therapies, appealing to medical institutions needing efficient administration solutions. The company's revenue streams come from the sale of Niyad, LTX-608, Fedsyra, and PFS-02 to healthcare providers. Hospitals and dialysis centers are key buyers for Niyad, while LTX-608 targets hospitals managing viral outbreaks and severe inflammatory conditions. Fedsyra and PFS-02 are sold as complementary products to support the delivery of nafamostat therapies, with demand driven by the need for specialized medical treatments in supervised care settings. Talphera is one of the most popular companies on Eulerpool.

ROE Details

Decoding Talphera's Return on Equity (ROE)

Talphera's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Talphera's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Talphera's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Talphera’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Talphera stock

Return on Equity (ROE) of Talphera is -83.89 % in 2025.

Return on Equity (ROE) of Talphera changed from -162.53 % to -83.89 %, representing a -48.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Talphera since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Talphera with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Talphera

All Key Metrics — Talphera